AptarGroup Earnings Call Transcripts
Fiscal Year 2026
-
Global operations delivered $3.8B in 2025 revenue, led by pharma, with strong innovation and a robust patent portfolio. Pharma remains the growth engine, supported by a diversified pipeline and new drug delivery technologies. Beauty and closures segments are recovering, with margin improvements expected as operational challenges are resolved.
-
Global operations generated $3.8 billion in 2025, with Pharma as the main growth engine and a diverse, innovation-driven pipeline supporting a 7%-11% long-term growth target. Recent investments focus on automation, while injectables and high-value products show strong momentum.
-
The meeting confirmed leadership succession, approved all voting items, and highlighted strong 2025 financial results, including increased sales and dividends. Strategic focus remains on Pharma growth, sustainability, and operational efficiency.
-
Sales rose 11% year-over-year, but core sales were flat as emergency medicine destocking weighed on pharma. Beauty and closures saw margin pressure from mix and operational issues, but sequential improvements are expected. Free cash flow doubled and $131 million was returned to shareholders.
-
A global leader in drug and consumer product dispensing, the company reported $3.8 billion in 2025 revenue, with pharma as its core growth engine. Strong innovation, a diversified pipeline, and sustainability leadership support long-term growth, with margin improvements expected across all segments in 2026.
-
Proprietary drug delivery systems are expanding into new therapeutic areas, with strong growth in injectables and consumer businesses. The company maintains stable guidance and expects margin improvement as operational efficiencies and product mix evolve. Emergency medicine destocking is largely contained to the first half of the year.
-
Pharma leads with proprietary drug delivery and robust IP, driving two-thirds of EBITDA and a strong, expanding pipeline. Capital allocation remains balanced, with high investment in growth and record share buybacks. Nasal and injectable innovations, digital health partnerships, and global expansion underpin future growth.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong sales growth and robust innovation, with all segments delivering core sales gains. Margins were pressured by mix and operational issues, but sequential improvement is expected in 2026. Emergency medicine remains a headwind, but pharma, beauty, and closures show positive momentum.
-
Pharma drives growth and profitability, with proprietary drug delivery systems and a robust pipeline in chronic and emerging therapies. Injectables and nasal delivery are key growth areas, supported by steady CapEx, targeted M&A, and increased share repurchases amid strong shareholder returns.
-
Q3 saw adjusted EPS of $1.62, with pharma growth in injectables and drug delivery, offset by consumer healthcare destocking. Emergency medicine faces a 35% revenue decline in 2026, compressing margins, but long-term pharma growth targets remain intact.
-
Raised ROIC and dividend targets reflect strong execution, with all segments contributing to profitable growth. Pharma leads with innovation and a robust pipeline, while Beauty and Closures drive efficiency and regional expansion. Sustained cost management, automation, and disciplined capital allocation underpin long-term targets.
-
Q2 results exceeded guidance with 18% EPS growth and strong performance across all segments, led by Pharma and Closures. Outlook for Q3 is cautious due to naloxone normalization, legal expenses, and ongoing European inventory headwinds, but innovation and capital returns remain robust.
-
Pharma is the primary growth engine, supported by proprietary technology, global operations, and a strong sustainability focus. Financial targets were raised in 2023, with robust pipeline diversification and disciplined capital allocation. Digital health and innovative packaging drive additional growth.
-
The event highlighted robust long-term growth targets, a strong balance sheet, and disciplined capital allocation, with pharma as the main growth driver. Beauty and closures segments are positioned for recovery, while a resilient supply chain mitigates tariff and geopolitical risks.
-
Adjusted EPS rose 5% year-over-year (currency and tax neutral), with pharma and active materials driving growth despite flat core sales and a 3% FX headwind. Beauty and closures showed sequential improvement, and Q2 guidance anticipates stronger EPS and limited tariff impact.
-
Pharma is the largest and fastest-growing segment, driving value through proprietary technology, global reach, and sustainability leadership. Growth is fueled by innovation in nasal and injectable drug delivery, robust pipeline management, and digital health expansion. Financial targets have been raised, with strong capital allocation and a focus on operational excellence.
Fiscal Year 2024
-
Q4 core sales grew 2% and adjusted EPS rose 27% year-over-year, driven by strong Pharma and closure segment performance, margin expansion, and operational efficiencies. 2025 guidance anticipates FX and tax headwinds, but normalized EPS growth is expected to remain strong.
-
Q3 saw 2% core sales growth and 6% higher adjusted EPS, with pharma and closures segments driving performance. Full-year double-digit EPS growth is expected, supported by strong pharma demand, innovation, and disciplined capital allocation.
-
Core sales grew 3% and adjusted EPS rose 12% year-over-year, driven by strong pharma demand and margin expansion. Pharma led with 7% core sales growth, while beauty and closures saw mixed results. Outlook remains positive, with continued investment in innovation and sustainability.